CLRB Financial News

42.8% ORR in multiple myeloma at the 75mCi total body dose 42.0% ORR and 11% CRR in all non-Hodgkin’s lymphoma (NHL) patients 100% ORR seen in Lymphoplasmacytic.

FLORHAM PARK, N.J., Jan. 09, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

FLORHAM PARK, N.J., May 07, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving.

FLORHAM PARK, N.J., Dec. 19, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as Chief Medical Officer. Igor Grachev, M.D., Ph.D., brings nearly 20 years of industry experience to Cellectar having led clinical development programs at both multinational pharmaceutical and biotech organizations.

50% overall response rate in cohort of patients receiving fractionated 37.5 mCi/m2 dose of CLR 131 31.3% overall response rate in multiple myeloma patients over all dose levels,.

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

If you own shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) then it's worth thinking about how it contributes to...

FLORHAM PARK, N.J., Oct. 30, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

FLORHAM PARK, N.J., Dec. 02, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

FLORHAM PARK, N.J., Jan. 06, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

We can readily understand why investors are attracted to unprofitable companies. For example, although...

FLORHAM PARK, N.J., Oct. 17, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

FLORHAM PARK, N.J., Dec. 13, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

FLORHAM PARK, N.J., May 14, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

FLORHAM PARK, N.J., March 09, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

Companies In The News Are: EVFM, BNFT, SRNE, CLRB

FLORHAM PARK, N.J., Nov. 12, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received two prior treatment regimens or more. CLR 131 is the company’s small-molecule, cancer-targeting radiotherapeutic Phospholipid Drug Conjugate™ (PDC™) designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.

CLRB News

Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

Cellectar Biosciences to Present at Biotech Showcase 2020

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

Here's Why We're A Bit Worried About Cellectar Biosciences's (NASDAQ:CLRB) Cash Burn Situation

Should You Be Concerned About Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) Historical Volatility?

Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

Company News for May 27, 2020

Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia